P | X2 | Arm 2 WBRT only | Arm1 irinotecan and WBRT | Variables | ||
>0.05 NS | 0.6 | 57.1 + 9 | 55.6 + 10 | Age (mean + SD) | ||
|
|
|
| (ECOG P S) | ||
>0.05 NS | 0.2 | 6 (24%) | 5 (20%) | 0 | ||
15 (60%) | 15 (60%) | 1 | ||||
4 (16%) | 5 (20%) | 2 | ||||
>0.05 NS | 1.2 |
16 (64%) 9 (36%) |
15 (60%) 10 (40%) | Gender Male Female | ||
>0.05 NS | 4 | 5 (20%) | 7 (28%) | Primary tumor Breast | ||
15 (60%) | 14 (56%) | Lung | ||||
2 (8%) | 1 (4%) | Melanoma | ||||
1 (4%) | 1 (4%) | Colon | ||||
0 | 1 (4%) | Parotid | ||||
0 | 1 (4%) | Unknown | ||||
1 (4%) | 0 | | ||||
1 (4%) | 0 | Ovary | ||||
|
|
|
| Number of brain metastases | ||
>0.05 NS | 2.2 | 2 (8%) | 0 | 1 | ||
2 (8%) | 2 (8%) | 2 | ||||
2 (8%) | 3 (12%) | 3 | ||||
19 (76%) | 20 (80%) | >3 | ||||
|
|
| extracerebral metastasis | |||
>0.05 NS | 12 (48%) | 10 (40%) | No | |||
13 (52%) | 15 (60%) | Yes | ||||
|
|
| previous chemotherapy | |||
(>0.05 NS | 12 (48%) | 9 (36%) | No | |||
13 (52%) | 16 (64%) | Yes | ||||